Abeona Therapeutics (ABEO) Competitors

Adagene (NASDAQ:ADAG) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.

Do analysts prefer ADAG or ABEO?

Adagene currently has a consensus price target of $5.00, indicating a potential upside of 275.94%. Abeona Therapeutics has a consensus price target of $40.00, indicating a potential upside of 995.89%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Abeona Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ADAG or ABEO?

Abeona Therapeutics received 495 more outperform votes than Adagene when rated by MarketBeat users. However, 76.19% of users gave Adagene an outperform vote while only 71.17% of users gave Abeona Therapeutics an outperform vote.

Company	Underperform	Outperform
Adagene	Outperform Votes 16 76.19%	Underperform Votes 5 23.81%
Abeona Therapeutics	Outperform Votes 511 71.17%	Underperform Votes 207 28.83%

Does the media prefer ADAG or ABEO?

In the previous week, Abeona Therapeutics had 6 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Abeona Therapeutics and 0 mentions for Adagene. Abeona Therapeutics' average media sentiment score of 0.57 beat Adagene's score of 0.49 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Abeona Therapeutics	Positive

Which has more risk and volatility, ADAG or ABEO?

Adagene has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Which has higher valuation & earnings, ADAG or ABEO?

Abeona Therapeutics has lower revenue, but higher earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$9.29 million	6.19	-$79.97 million	N/A	N/A
Abeona Therapeutics	$1.41 million	44.09	-$39.70 million	N/A	N/A

Is ADAG or ABEO more profitable?

Adagene's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Abeona Therapeutics	N/A	-132.14%	-53.24%

Do insiders & institutionals have more ownership in ADAG or ABEO?

13.7% of Adagene shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abeona Therapeutics beats Adagene on 8 of the 13 factors compared between the two stocks.